Asklepios BioPharmaceutical, Inc. (AskBio)’s Post

More exciting news from my team!

How can we spread, scale & sustain life-saving treatments for disease? Moving #evidencebased therapies for cardiovascular-kidney-metabolic (#CKM) into action could be easier if partners come together. Read about what clinical researchers, payers, funders, journal editors, association, quality, and pharmaceutical industry leaders had to say about #knowledgetranslation at the DCRI’s #Implementation Summit. https://duke.is/imp-summit

🎉 Exciting News: for Diabetic patients #Evapharma Introducing Mellitofix TRIO, a groundbreaking pharmaceutical innovation designed to revolutionize healthcare. Backed by years of rigorous research and development trials, MELLITOFIX TRIO promises to redefine #diabetestreatment standards, offering hope to millions worldwide. Learn more about this transformative advancement in medicine! BY asking your physician #HealthcareInnovation #BreakthroughTreatment #evapharma #diabetes

What is needed to improve the transfer of ideas from bench to bedside, to provide more effective treatments for "patients" in need? How can stakeholders in the healthcare ecosystem—including patient groups, scientists, investors, the pharmaceutical industry and med-tech innovators—collaborate to improve and accelerate processes in the search for better outcomes, and even cures? From bench to bedside—accelerating progress in healthcare innovations | Feb 7th 2024 | https://lnkd.in/dzpTZSwm Parkinson's Europe

MARKET ACCESS SURVEY: 47% of payers, IDNs, and other stakeholders plan to execute a prescription digital therapeutics strategy by 2025, according to our Second Annual Market Access Survey. - 40% say they will execute #AI plans by 2025 for administrative and manual functions, including streamlining prior authorization. “Organizations desire additional clarity regarding the value of prescription therapeutics and reimbursement,” says our colleague Tony Gibson. “CMS and FDA activity in this area will also spur payer planning in this area.” #marketaccess #pharma #biotech

Amylyx Pharmaceuticals' ALS drug, Relyvrio, didn't meet its goals in the crucial Phase III trial, casting uncertainty on its future. Despite this, the drug's safety profile remained consistent. Considerations - 🔹 The impact on ALS treatment advancements and patient hope. 🔹 Potential regulatory discussions and the commitment to patient well-being may guide Amylyx's next steps. This setback in ALS research emphasizes the challenges in neurodegenerative disease treatment but also the unwavering quest for solutions. #ALS #HealthcareNews #ClinicalTrials

We’re raising awareness for #biosimilars and the important role they play in expanding access to care in healthcare systems around the globe. At Teva, we believe that unlocking value in biologics is essential, and that value creation is the key to broadening patient access and lowering system costs around the globe. Together we can make a difference in the lives of patients through policies that support #biosimilar adoption and education. Discover the magic of biosimilars here. https://lnkd.in/dBvZfHyc #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm

85% of clinical trials struggle with patient recruitment, and 80% face delays due to factors such as participant dropouts, impacting the development of life-changing medicine. As 2024 gets underway, clinical trial stakeholders are witnessing transformative trends aimed at addressing these pain points. Our latest blog outlines critical considerations for pharmaceutical sponsors and contract research organizations (CROs) to keep top of mind in the new year. Read more in "Enhancement, Efficiency, Equity, and Engagement: Four Trends Shaping Clinical Trials in 2024" > https://bit.ly/48CTaqU #ACRP #ClinicalResearch #ClinicalTrials #Blog #PatientRecruitment #Trends

How can we make clinical trials more diverse and easier for the patients taking part? Decentralized clinical trials have the potential to boost patient diversity, increase patient-centricity and improve trials for all stakeholders.   In a recent article, I share my thoughts and experiences of decentralization and the benefits for patients, sponsors and industry as a whole, including:   –     its impact so far –     why the pharmaceutical industry is holding back –     next steps and why it’s time to think big.   Plus I share how Cerba Research is embracing decentralization as a key part of our mission to transform research and advance health.   You can read the full article here https://lnkd.in/eTPHP3df

FDA Approves Eli Lilly’s Donanemb to Treat Alzheimer’s Disease 🎉 Great news for Alzheimer’s treatment! 🎉 The FDA has approved Eli Lilly's drug donanemab, adding a new tool to fight this tough disease. Although there are some concerns about its safety and effectiveness, experts are hopeful. 💰Positive reviews and an estimated $8 billion market value suggest this could be a big breakthrough. 🙌 This benefits both patients and the pharmaceutical industry. Donanemab gives new hope to Alzheimer’s patients by potentially slowing down the disease and improving their quality of life. For the pharma industry, it’s a big opportunity to fund more research in this important field. 🚪 Donanemab’s approval opens the door for even better treatments in the future. 🌟The pharma industry can leverage this momentum to accelerate research and deliver even better outcomes for Alzheimer's patients. #Alzheimers #ClinicalTrials #innovation